December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fennec Pharmaceuticals Inc. - Common Stock (NQ:FENC)

8.685 -0.085 (-0.97%)
Streaming Delayed Price Updated: 12:41 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fennec Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter ↗
Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside... 
Via MarketBeat
Topics Intellectual Property
News headline image
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fennec Pharmaceuticals Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Fennec (FENC) Q1 2026 Earnings Call Transcript ↗
Fennec (FENC) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Fennec Pharmaceuticals (NASDAQ:FENC) Q1 Beat Overshadowed by Surging Costs ↗
Via Chartmill
News headline image
Adherex Technologies Q1 Earnings Call Highlights ↗
Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow... 
Via MarketBeat
Topics Earnings
News headline image
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Fennec Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
From Fennec Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
From Fennec Pharmaceuticals Inc.
Via GlobeNewswire
Fennec Pharmaceuticals (NASDAQ:FENC) Reports Q4 2025 Revenue Growth but Misses Earnings Estimates ↗
Via Chartmill
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
Fennec Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Fennec Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year ↗
This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands. 
Via The Motley Fool
News headline image
Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in Revenue ↗
Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets. 
Via The Motley Fool
News headline image
Solas Capital Loads Up On Kyndryl With 407,000 Shares Bought ↗
This technology firm delivers IT infrastructure and managed solutions to major enterprises across multiple global industries. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Fennec Q2 Sales Jump 33 Percent ↗
Via The Motley Fool
News headline image
Fennec (FENC) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Reports Mixed Q2 2025 Earnings with Revenue Slight Miss and Wider-Than-Expected Loss ↗
Fennec Pharmaceuticals reported mixed Q2 2025 results, missing revenue estimates by 0.6% and posting a wider EPS loss. PEDMARK® growth and new accounts drove optimism despite financial... 
Via Chartmill
News headline image
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? ↗
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir... 
Via Benzinga
Topics Economy Stocks
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 10, 2025 ↗
 
Via Benzinga
News headline image
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ↗
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! ↗
These dirt cheap stocks under $10 have the potential to rise rapidly and create fortunes for bold investors. 
Via InvestorPlace
News headline image
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
FENC stock results show that Fennec Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 ↗
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For March 21, 2024 ↗
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Highlighted for Surprising Price Action
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.